Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This is a phase 2a trial testing twice daily administration of LEO 124249 ointment 30 mg/g in
the treatment of mild to moderate inverse psoriasis. Patients will be treated for 6 weeks,
and the efficacy and safety will be compared with the treatment of LEO 124249 ointment
vehicle.